AI platform co-founder: building the ‘holy grail’ for chemical patents

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

AI platform co-founder: building the ‘holy grail’ for chemical patents

5mins.jpg

Tamar Gomez, our latest ‘Five minutes with’ subject, discusses Markush formula descriptions, spinning plates and why her role is both exhilarating and terrifying

Welcome to the latest instalment of Managing IP’s ‘Five minutes with’ series, where we learn more about intellectual property practitioners on a personal and professional level. This time, we meet Tamar Gomez at Ankar AI, an artificial intelligence platform for inventors.

Someone asks you at a party what you do for a living. What do you say?

I help inventors create the ideas that solve the world’s toughest challenges

Talk us through a typical working day.

Wake up, coffee, run – that’s the calm. Then comes the storm: patents, AI, customers and a dash of chaos. Wouldn’t have it any other way.

What are you working on at the moment?

Right now, I’m working with chemists and drafters to build an AI assistant that writes crystal-clear Markush formula descriptions – the holy grail for chemical patents.

Does one big piece of work usually take priority or are you juggling multiple things?

As a founder, I’m always spinning plates: hiring brilliant people, talking to customers, and pushing the product forward. It’s a juggling act, and honestly, I love it.

What is the most exciting aspect of your role and what is the most stressful?

They’re the same: building the next generation of tools for inventors. It’s exhilarating and terrifying in equal measure.

Tell us the key characteristics that make a successful IP lawyer/practitioner.

I’m not an IP lawyer myself, but the best I’ve seen combine big-picture strategy with an obsession for detail. It’s a rare and powerful mix.

What is the most common misconception about IP?

That it’s niche! In reality, IP is how society values ideas. Without it, innovation would grind to a halt.

What or who inspires you?

My cofounder, Wiem Gharbi, inspires me daily – she’s unstoppable. And our team at Ankar: fiercely clever, endlessly resilient, never backing down.

If you weren’t in IP, what would you be doing?

I would be a soldier.

Any advice you would give your younger self?

You’ll figure it out

What is your motto in life?

À la vie, à la mort!

To find out more about Ankar AI, visit its website.

more from across site and SHARED ros bottom lb

More from across our site

Examiner statistics could help patent prosecution practitioners tailor strategies, turning an area of high variability into a potential competitive advantage
The England and Wales High Court’s ruling in Accord v Novartis may not rewrite the law on plausibility, but it does signal a pragmatic approach that could provide greater certainty for life sciences innovators
Firms with established sports relationships and specialised expertise are well positioned to capture the market’s expanded pool of IP work
Gunjan Paharia discusses developing RIA, an AI platform built to draw on decades of institutional knowledge, support junior lawyers, and reshape how legal teams work
A strong Canadian business helped lift profits, but the IP service group's latest results underline the pressure facing its operations in Australia, New Zealand and parts of Asia
Wins in court have been key to the six-year-old firm’s growth, as one of its founders explains
The firm’s co-CEO discusses patent litigation, collaboration with overseas colleagues and the next generation of leaders
Two recent decisions demonstrate the courts’ creativity in cutting-edge IP disputes that tested their jurisdictional powers
Aditi Verma Thakur, managing partner at Aishani Partners, discusses 5 am wake-ups, working with high-performing professionals and staying calm under pressure
After more than three decades at Wilson Sonsini, Ian Edvalson explains why he moved to expand his life sciences transactional practice
Gift this article